LMO2 and diffuse large B-cell lymphoma: Moreover, LMO2 expression is associated with improved survival in Diffuse Large B-Cell Lymphoma (DLBCL), possibly due to its inhibitory effect on HRR activity in DLBCLs, thus providing a rationale for the therapeutic use of PARPi in LMO2-positive DLBCLs25.